Business, energy, technology, markets and global industry news from Business News Today

Merck KGaA

PharmaDeviceNews Merck KGaA
Medical Devices & Diagnostics Pharma & Biotech

Merck KGaA just made a quiet digital-health move. Could hybrid drugs be pharma’s next big reset?

Digital therapeutics struggled alone. Remepy and Merck KGaA are testing whether software works better when built into the drug itself.

Read More
Representative image of a knee joint affected by tenosynovial giant cell tumor (TGCT), the rare condition targeted by pimicotinib, now under FDA review for potential approval as a first-in-class oral CSF-1R inhibitor.
Pharma & Biotech

FDA accepts pimicotinib NDA for TGCT: What this signals for rare tumor drug development and the CSF-1R inhibitor class

Find out how Abbisko’s TGCT drug pimicotinib just crossed a major milestone with the FDA—and what this means for patients and the CSF-1R class.

Read More